were selected: 1) to analyze the changes of heart failure manifestations and exercise tolerance in patients after transplantation of cord blood cells; 2) to analyze the short-term and medium-term effectiveness of conservative treatment after transplantation of cord blood cells; 3) to analyze changes in biochemical markers of heart failure and estimated cardiovascular disease mortality risk after transplantation of cord blood cells.
The trial is based on the results of a prospective non-randomized observation study without a control group in 20 patients (clinical characteristics of patients are presented in Table. 1) that underwent cord blood total nucleated cells (CB TNCs) transplantation, combined with traditional drug therapy. The study was carried out under the R&D project of Shalimov National Institute of Surgery and Transplantology NAMS of Ukraine. The collection and storage of umbilical cord blood was performed in accordance with the current legislation of Ukraine, in compliance with generally accepted ethical aspects and the permission of the Coordination Center of Transplantation of Organs, Tissues and Cells of the Ministry of Health of Ukraine and approval of the medical ethics committee of Shalimov National Institute of Surgery and Transplantology on 29/07/2013.
The criteria for inclusion in the study group were age 20 to 60 years, HF stage IIA-IIB, functional class (FC) III or IV according to New York Heart Association (NYHA), reduced left ventricular ejection fraction (less than 35 %). At the start of the study the written informed consent was obtained. All patients undertake to comply with medication therapy and notify about all other drugs. Exclusion criteria of participants in the study were: patient's refusal to participate; severe complications; decompensated concomitant diseases or acute illness that can significantly affect the results of the study; the use of not recommended drugs; oncological or psychiatric anamnestic history (Tab. 1).
Collecting of cord blood and transplantation of the cell was carried out by the written informed consent of donor and recipient representatives. Cell viability and required biosafety parameters have been certified in the analytical passport that was provided for each individual dose of the cell drug by the manufacturer (Institute of Cell Therapy, Kyiv). For each dose of the cell drug there was performed a microbiological study and polymerase chain reaction to exclude markers of transmissible infections in cord blood and maternal blood (HIV 1/2, Treponema pallidum, Toxoplasma gondii, CMV, HCV, HBcorAg, HBsAg).
CB TNCs transplantation was performed as a single injection of washed from cryoprotector cell preparation «Cryopreserved human cord blood» washed from cryoprotector by intravenous infusion at a speed of 20-25 drops per minute in 200 mL of saline. The dose of cell preparation (4.5 mL suspension) included from 0.89•10 9 to 0.95•10 9 nucleated cells including mononuclear cells from 0.486•10 9 to 0.52•10 9 with viability 98-99 %. Complex examination of patients was carried out before CB TNCs transplantation and 1, 3, 6 and 9 months after it. Echocardiographic examination of patients was performed by ultrasound scanner Aplio 500 (Toshiba, Japan). For the assessment of intracardiac hemodynamic parameters and systolic and diastolic functions of the cardiac muscle, conventional methods were used [5] . Clinical assessment of systolic and diastolic dysfunction by echocardiography data-tests were performed according to the «Guidelines for diagnosis and treatment of chronic heart failure». The results of echocardiography study after CB TNCs transplantation generalized by observations stages are presented in Table 2 .
Exercise tolerance and functional class of HF was determined by the results of six-minute walk test (6MWT). Objectification of HF severity was performed by levels of the brain natriuretic peptide precursor (NTproBNP) according to current recommendations [7] . The assessment of cardiovascular disease mortality risk was carried out using the Metaanalysis Global Group in Chronic Heart Failure (MAGGIC) score [10, 13] .
Statistical analysis of the data was performed by conventional methods using two-sample Student's t-test with unequal variances. Differences were considered significant at p < 0.05.
Over the entire period of observation there was not registered an increase of clinical manifestations of HF, except two patients: one patient had HF decompensation caused by systematic abuse of prescribed drug therapy. Another patient had significant concomitant non-cardiac disease, which in combination with HF progressing led to the death of the patient on the 2 nd month of observation. CB TNCs transplantation allowed to improve significantly the general well-being of patients with HF refractory to conventional therapy (Tab. 3).
According to the table, there was registered a steady improvement of HF FC by NYHA till the sixth month of observation after CB TNCs transplantation. At the end of the 9 th month of observation the average FC of patients slightly regress relatively to previous maximum values, but was significantly higher than the initial value.
The above changes of HF FC were confirmed by an increase in the distance covered during the 6MWT (Tab. 4). 
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The majority of patients (80 % before CB TNCs transplantation) received bisoprolol (Concor, Takeda, Japan) as a beta-blocker. carvedilol (Kyiv Vitamin Factory, Ukraine) was used in 20 % of patients with reduced ejection fraction (up to 20 %) due to alpha-adrenergic blocking effects. Angiotensin-converting-enzyme (ACE) inhibitors were used only in 50 % patients and in minimal doses, due to arterial hypotension. The main ACE inhibitor was ramiprilum (Tritace, Sanofi-Aventis S.p.A., Italy). For patients, who came to hospital with optimally prescribed doses of captopril (Kyivmedpreparat, Ukraine), the drug was not changed.
HF progression was not found in the patients, except two cases. Average doses of beta-blockers and ACE inhibitors remained relatively stable throughout the study: mean dose of bisoprolol was 2.4-3.1 mg/day, carvedilol -6.25-7.8 mg/day, ramiprilum -2.0-2.5 mg/day, captopril -4.68-6.25 mg/day.
All patients with refractory HF had an increased cardiovascular disease mortality risk (see Tab th and 9 th months of observation, respectively. Reduction of the cardiovascular disease mortality risk, compared with the initial state, can provide an opportunity to extend waiting period for heart transplantation.
According to the table, the exercise tolerance increased significantly to the third month of observation after CB TNCs transplantation. In the period from the 3 rd to the 9 th month of observation, despite the negative trend relatively to the level of the best indexes, covered distance was significantly higher than the rates in these patients before CB TNCs transplantation (p < 0.05). Full compensation of HF clinical symptoms was achieved by the end of the 3 rd month of observations, and a positive effect was kept to the end of the observation period.
Objective confirmation of the reduction of HF clinical manifestations was positive dynamics of the brain natriuretic peptide precursor. The most significant decrease in NT-proBNP level was registered in the 1st month of observation with the lowest level of it in the 3 rd month. At the end of the 6 th and 9 th months of observation a tendency to decrease in NT-proBNP levels was also registered, as compared to the initial state.
During the observation by the end of the first month after CB TNCs transplantation there was a significant reduces of edema symptoms compared with the initial state. At reducing of HF manifestations an enhancement of diuretic efficiency was observed. After CB TNCs transplantation the average doses of diuretic drugs were reduced: 38,4-41,4 % for spironolactone (Veroshpiron, Gedeon Richter, Hungary) and 31,2-48,4 % for furosemide (Borshchahivskiy CPP, Ukraine), compared with the initial state. One patient after CB TNCs transplantation needed a 2-3 multiple intravenous injection of Furosemide (as a result of an abuse of prescribed drug therapy) followed by peroral administration of veroshpiron and furosemide. Table 4 . Changes in 6-min walk distance, the level of NT-proBNP, one-and three-year mortality risk by MAGGIC score in patients before and after CB TNCs transplantation.
